Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission : autologous LAK cells following allogeneic bone marrow transplantation are donor-derived

A 48-year-old man was treated by allogeneic bone marrow transplantation (BMT) in first remission of M4 acute myelogenous leukaemia (AML). He experienced no graft-versus-host disease (GVHD) and 7 months later he relapsed. Following further chemotherapy, he entered a second complete remission; however...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology Immunotherapy 1995-07, Vol.41 (1), p.68-70
Main Authors: BOUGHTON, B. J, SIMPSON, A. W, PHAURE, T. A. J, BEATTY, C
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Bone Marrow Transplantation - pathology
Genetic Markers
Graft vs Host Disease - immunology
Graft vs Host Disease - pathology
Humans
Immunotherapy
Interleukin-2 - therapeutic use
Killer Cells, Lymphokine-Activated - immunology
Leukemia, Myeloid, Acute - therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Short Communication
Tissue Donors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 48-year-old man was treated by allogeneic bone marrow transplantation (BMT) in first remission of M4 acute myelogenous leukaemia (AML). He experienced no graft-versus-host disease (GVHD) and 7 months later he relapsed. Following further chemotherapy, he entered a second complete remission; however, he refused a further allogeneic or autologous BMT but agreed to immunotherapy with interleukin-2 and autologous lymphokine-activated killer (LAK) cells. He tolerated this treatment well but went on to develop grade II skin GVHD. Polymerase chain reaction studies of DNA microsatellites of the autologous LAK cells showed that they were of donor origin. The patient remained well for 9 months until, immediately following the introduction of prednisolone for his persistent GVHD, he relapsed. He declined further active treatment and died 5 months later. The case shows that IL-2/LAK cells can be safely given to patients who have experienced no GVHD following allo-BMT and are likely to be effective through an ongoing graft-versus-leukaemia effect.
ISSN:0340-7004
1432-0851
DOI:10.1007/BF01788962